Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 15
Safety and Efficacy of Janus Kinase Inhibitors
Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.
Video content above is prompted by the following:
Results from the 2021 ORAL Surveillance study showed the Janus kinase inhibitor (JAKi) tofacitinib was associated with a cardiovascular and cancer risk.
- Can you describe concerns and misperceptions that ensued from results of the ORAL Surveillance study? What were the limitations of the study?
- Can you please share how you weigh JAKi safety concerns with their efficacy outcomes?
- In your clinical observations, what role have JAKis played in helping patients with rheumatoid arthritis achieve remission?
